drugset / Trial / NCT05323019
Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression
RandomizedParallel-groupSingle-blindTreatment
Summary
To examine the efficacy of Almond Therapy compared to Treatment as Usual when used in addition to an approved version of intranasal esketamine.
Timeline
- Start
- 2022-10-13
- Primary completion
- 2023-02-01
- Completion
- 2023-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Esketamine | Other / unclassified | 56 mg | Intranasal |
| Subject | Esketamine | Other / unclassified | 84 mg | Intranasal |